Nanotechnology Reviews,
Journal Year:
2024,
Volume and Issue:
13(1)
Published: Jan. 1, 2024
Abstract
Immunotherapy
is
currently
the
main
treatment
for
malignant
tumors
by
activating
immune
cell.
Metabolic
reprogramming
in
tumor
microenvironment
can
greatly
affect
function
of
cell,
and
T
cell
anti-tumor
effector
Therefore,
cell-based
immunometabolic
therapy
improve
clinical
efficacy.
In
therapy,
regular
agents
conventional
forms
are
difficult
to
achieve
intended
efficacy
due
poor
permeability
low
cellular
uptake.
Nanoparticle-based
strategy
serve
as
optimal
targeted
drug
delivery
system
co-encapsulation
multiple
therapeutic
stable
loading.
Here,
we
intend
summarize
examples
nanoparticles
provide
a
comprehensive
helpful
review
covering
notable
vital
applications
nanotechnology-based
strategies
therapy.
View,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 20, 2025
Abstract
The
precision
of
cancer
immunotherapy
is
critically
dependent
on
accurately
characterizing
the
tumor
immune
microenvironment
(TIME),
which
represents
a
complex
interplay
cellular
components,
cytokines,
and
metabolic
factors.
Traditional
diagnostic
methods
lack
resolution
to
capture
dynamic
molecular
interactions
within
TIME
at
microscale
level.
This
review
focuses
recent
advancements
in
measurements
for
identifying
novel
immune‐oncology
biomarkers
therapeutic
targets
TIME,
emphasizing
importance
high‐fidelity
data
infiltrates
significance
longitudinal
high‐dimensional
analysis
predicting
treatment
responses.
Furthermore,
discusses
impact
reprogramming
potential
new
responses
immunotherapy.
role
nanotechnology
enhancing
detection
checkpoints
development
AI‐based
sensors
real‐time
predictive
modeling
also
explored,
highlighting
these
advanced
technologies
revolutionize
field
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
14(4)
Published: Nov. 12, 2024
Tumor
metabolism
is
crucial
in
the
continuous
advancement
and
complex
growth
of
cancer.
The
emerging
field
nanotechnology
has
made
significant
strides
enhancing
understanding
metabolic
intricacies
inherent
to
tumors,
offering
potential
avenues
for
their
strategic
manipulation
achieve
therapeutic
goals.
This
comprehensive
review
delves
into
interplay
between
tumor
various
facets
cancer,
encompassing
its
origins,
progression,
formidable
challenges
posed
by
metastasis.
Simultaneously,
it
underscores
classification
programmable
nanomodulators
transformative
impact
on
cancer
treatment,
particularly
when
integrated
with
modalities
such
as
chemotherapy,
radiotherapy,
immunotherapy.
also
encapsulates
mechanisms
which
modulate
metabolism,
including
delivery
inhibitors,
regulation
oxidative
stress,
pH
value
modulation,
nanoenzyme
catalysis,
nutrient
deprivation,
RNA
interference
technology,
among
others.
Additionally,
prospects
clinical
applications.
Finally,
innovative
concept
using
reprogram
pathways
introduced,
aiming
transform
cells
back
normal
cells.
profound
that
tailored
can
have
metabolic,
charting
a
path
toward
pioneering
precision
therapies
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(12), P. 1527 - 1527
Published: Nov. 27, 2024
Cancer,
the
most
common
condition
worldwide,
ranks
second
in
terms
of
number
human
deaths,
surpassing
cardiovascular
diseases.
Uncontrolled
cell
multiplication
and
resistance
to
death
are
traditional
features
cancer.
The
myriad
treatment
options
include
surgery,
chemotherapy,
radiotherapy,
immunotherapy
treat
this
disease.
Conventional
chemotherapy
drug
delivery
suffers
from
issues
such
as
risk
damage
benign
cells,
which
can
cause
toxicity,
a
few
tumor
cells
withstand
apoptosis,
thereby
increasing
likelihood
developing
tolerance.
side
effects
cancer
often
more
pronounced
than
its
benefits.
Regarding
drugs
used
their
bioavailability
stability
microenvironment
important
that
need
immediate
addressing.
Hence,
an
effective
reliable
system
through
both
rapid
precise
targeting
be
achieved
is
urgently
needed.
In
work,
we
discuss
development
various
nanobased
carriers
advancement
therapy—their
properties,
potential
polymers
for
delivery,
recent
advances
formulations.
Additionally,
use
metabolism-rewriting
nanomedicines
strengthening
antitumor
immune
responses
mRNA-based
nanotherapeutics
inhibiting
progression.
We
also
examine
several
issues,
nanotoxicological
studies,
including
distribution,
pharmacokinetics,
toxicology.
Although
significant
attention
being
given
nanotechnology,
equal
needed
laboratories
produce
so
they
record
themselves
clinical
trials.
Furthermore,
these
medicines
trials
display
overwhelming
results
with
reduced
effects,
well
ability
modify
dose
drug.
Discover Oncology,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: July 20, 2024
Abstract
Background
Chemokine
ligand
14,
which
has
a
C–C
motif
(CCL14),
mediates
the
immunological
milieu
around
tumors.
However,
its
role
in
progression
of
lung
adenocarcinoma
(LUAD)
is
still
unknown.
Our
objectives
were
to
study
association
between
CCL14
and
tumor-infiltrating
immune
cells
(TIICs)
as
well
predictive
significance
LUAD.
Methods
The
expression
LUAD
was
examined
by
using
Oncomine,
Cancer
Genome
Atlas
(TCGA),
University
Alabama
at
Birmingham
CANcer
data
analysis
Portal
(UALCAN),
Human
Protein
databases.
To
determine
prognostic
LUAD,
researchers
used
Kaplan‒Meier
plotter
Gene
Expression
Profiling
Interactive
Analysis
(GEPIA,
version
2).
We
utilized
TIMER
GEPIA2
investigate
connection
TIICs.
set
enrichment
(GSEA)
test
for
functional
genes.
RT‒qPCR
measure
Cell
Counting
Kit-8,
Transwell,
wound
healing
assays
biological
CCL14.
Results
prognosis
patients
with
worse
when
low.
Statistical
revealed
that
mRNA
significantly
greater
epithelial
than
cell
lines
vitro.
Enhancing
reduced
migration,
invasion,
proliferation.
results
infiltration
research
showed
TIICs
positively
correlated.
Different
patterns
associated
also
shown
TIIC
markers.
According
GSEA,
histone
deacetylases,
G2/M
checkpoints,
Notch
signaling
pathways
low
expression.
Conclusions
anticipated
emerge
marker
therapeutic
target
due
regulating
TIICs,
suggesting
it
may
be
an
antioncogene.
Journal of Multidisciplinary Healthcare,
Journal Year:
2024,
Volume and Issue:
Volume 17, P. 5117 - 5137
Published: Nov. 1, 2024
Cancer
poses
a
major
global
health
challenge,
and
immunotherapy,
known
as
the
third
revolution
in
cancer
treatment,
has
brought
new
hope
to
patients.
The
emerging
field
of
immunometabolism
further
enhanced
safety
efficacy
immunotherapy.
Over
past
two
decades,
this
rapidly
evolved
oncology,
leading
numerous
significant
findings.
This
review
systematically
examines
literature
on
cancer,
visualizing
research
trends
identifying
future
directions.
Bioconjugate Chemistry,
Journal Year:
2024,
Volume and Issue:
35(8), P. 1116 - 1141
Published: July 16, 2024
The
clinical
treatment
of
glioma
remains
relatively
immature.
Commonly
used
treatments
for
gliomas
are
surgery
combined
with
chemotherapy
and
radiotherapy,
but
there
is
a
problem
drug
resistance.
In
addition,
immunotherapy
targeted
therapies
also
suffer
from
the
immune
evasion.
advent
metabolic
therapy
holds
immense
potential
advancing
more
efficacious
tolerable
against
this
aggressive
disease.
Metabolic
alters
processes
tumor
cells
at
molecular
level
to
inhibit
growth
spread,
lead
better
outcomes
patients
that
insensitive
conventional
treatments.
Moreover,
compared
therapy,
it
has
less
impact
on
normal
cells,
toxicity
side
effects,
higher
safety.
objective
review
examine
changes
in
characteristics
throughout
development
glioma,
enumerate
current
methodologies
employed
studying
metabolism,
highlight
reprogramming
pathways
along
their
mechanisms.
Importantly,
seeks
elucidate
targets
glioblastoma
(GBM)
summarize
effective
combination
strategies
based
various
studies.
